Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435821 | 1.00 | MGLL (0.56) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL29952776 | 0.90 | MGLL (0.56) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL3792767 | 0.86 | MGLL (0.61) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL591401 | 0.84 | MGLL (0.59) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL3782019 | 0.83 | MGLL (0.58) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL12892589 | 0.83 | MGLL (0.60) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL3758290 | 0.83 | MGLL (0.60) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL29952213 | 0.82 | MGLL (0.56) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL4875564 | 0.82 | MGLL (0.56) | MGLLTP53MAPTNPC1RAB9A | |
| SCHEMBL30853659 | 0.82 | MGLL (0.59) | MGLLTP53MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117645605-A | Preparation method of high-purity tedizolid phosphate intermediate | 安徽森吉制药有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116253711-A | Texazolamide phosphate intermediate and preparation method thereof | 浙江苏泊尔制药有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-114105946-A | Tedizolid phosphate intermediate and preparation method thereof | 浙江苏泊尔制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-2757104-B1 | COMPOUNDS USED IN THE SYNTHESIS OF OXAZOLIDINONES | MERCK SHARP & DOHME (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2346858-B1 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9328087-B2 | Methods for preparing oxazolidinones and compositions containing them | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2016041505-A1 | TEDIZOLID PHOSPHATE, INTERMEDIATE AND PREPARATION METHOD THEREOF | 正大天晴药业集团股份有限公司 | 2016-03-24 | — | — | WO | disclosed |
| US-20140206878-A1 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | TRIUS THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2757104-A1 | Compounds used in the synthesis of oxazolidinones | Trius Therapeutics (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8604209-B2 | Methods for preparing oxazolidinones and compositions containing them | TRIUS THERAPEUTICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2346858-A2 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | Trius Therapeutics (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100093669-A1 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | TRIUS THERAPEUTICS (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010042887-A2 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | TRIUS THERAPEUTICS (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206878-A1 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | OXA1L, MRPL21, SPOUT1 | MGLL 829/4885TP53 3141/4885MAPT 4653/4885 |
| US-20100093669-A1 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM | OXA1L, MRPL21, SPOUT1 | MGLL 829/4885TP53 3141/4885MAPT 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.